...
slrn-img

ACELYRIN, INC. Common Stock, Common Stock

SLRN

NSQ

$3.24

-$0.26

(-7.43%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$338.10M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
543.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.14 L
$8.88 H
$3.24

About ACELYRIN, INC. Common Stock, Common Stock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSLRNSectorS&P500
1-Week Return-13.79%-3.39%0.2%
1-Month Return-24.73%-1.92%2.72%
3-Month Return-20.09%-10.54%7.31%
6-Month Return-16.86%-4.47%10.44%
1-Year Return-51.99%4.06%27.53%
3-Year Return-80.56%0.94%30.88%

Financials

Dec '21Dec '22Dec '23
Total Revenue---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue--115.00K[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit--(115.00K)[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-11500000,"profit":false}]
Gross Margin---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses41.79M254.68M422.06M[{"date":"2021-12-31","value":9.9,"profit":true},{"date":"2022-12-31","value":60.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(41.79M)(254.68M)(422.06M)[{"date":"2021-12-31","value":-4179400000,"profit":false},{"date":"2022-12-31","value":-25468100000,"profit":false},{"date":"2023-12-31","value":-42206400000,"profit":false}]
Total Non-Operating Income/Expense(45.00K)8.58M70.98M[{"date":"2021-12-31","value":-0.06,"profit":false},{"date":"2022-12-31","value":12.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(41.84M)(250.46M)(381.64M)[{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}]
Income Taxes(41.79K)(4.17M)(52.90K)[{"date":"2021-12-31","value":-4179400,"profit":false},{"date":"2022-12-31","value":-417000000,"profit":false},{"date":"2023-12-31","value":-5289500,"profit":false}]
Income After Taxes(41.80M)(246.29M)(381.59M)[{"date":"2021-12-31","value":-4179720600,"profit":false},{"date":"2022-12-31","value":-24629100000,"profit":false},{"date":"2023-12-31","value":-38158810500,"profit":false}]
Income From Continuous Operations(41.84M)(250.46M)(381.64M)[{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}]
Income From Discontinued Operations---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(41.84M)(250.46M)(381.64M)[{"date":"2021-12-31","value":-4183900000,"profit":false},{"date":"2022-12-31","value":-25046100000,"profit":false},{"date":"2023-12-31","value":-38164100000,"profit":false}]
EPS (Diluted)--(4.35)[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-435,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SLRN
Cash Ratio 6.74
Current Ratio 7.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SLRN
ROA (LTM) -32.89%
ROE (LTM) -41.95%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SLRN
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SLRN
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.64
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.46

FAQs

What is ACELYRIN, INC. Common Stock share price today?

ACELYRIN, INC. Common Stock (SLRN) share price today is $3.24

Can Indians buy ACELYRIN, INC. Common Stock shares?

Yes, Indians can buy shares of ACELYRIN, INC. Common Stock (SLRN) on Vested. To buy ACELYRIN, INC. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLRN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ACELYRIN, INC. Common Stock be purchased?

Yes, you can purchase fractional shares of ACELYRIN, INC. Common Stock (SLRN) via the Vested app. You can start investing in ACELYRIN, INC. Common Stock (SLRN) with a minimum investment of $1.

How to invest in ACELYRIN, INC. Common Stock shares from India?

You can invest in shares of ACELYRIN, INC. Common Stock (SLRN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SLRN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ACELYRIN, INC. Common Stock shares
What is ACELYRIN, INC. Common Stock 52-week high and low stock price?

The 52-week high price of ACELYRIN, INC. Common Stock (SLRN) is $8.88. The 52-week low price of ACELYRIN, INC. Common Stock (SLRN) is $3.14.

What is ACELYRIN, INC. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ACELYRIN, INC. Common Stock (SLRN) is

What is ACELYRIN, INC. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ACELYRIN, INC. Common Stock (SLRN) is 0.64

What is ACELYRIN, INC. Common Stock dividend yield?

The dividend yield of ACELYRIN, INC. Common Stock (SLRN) is 0.00%

What is the Market Cap of ACELYRIN, INC. Common Stock?

The market capitalization of ACELYRIN, INC. Common Stock (SLRN) is $338.10M

What is ACELYRIN, INC. Common Stock’s stock symbol?

The stock symbol (or ticker) of ACELYRIN, INC. Common Stock is SLRN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top